Observational studyBMC cancer2018
Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
Observational study in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03474341 (Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Who cites it
30 citing papers in PubMed, 64 citations in OpenAlex.
- Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer UsingInternational journal of radiation oncology, biology, physics · 2020Trial
- MR-Guided Radiotherapy in Oesophageal Cancer: From Principles to Practice-A Narrative Review.Current oncology (Toronto, Ont.) · 2026Review
- Organ preservation in esophageal cancer treatment, is it time now?World journal of gastroenterology · 2025Review
- Pathologic complete response after neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Endoscopic characteristics and implications.Endoscopy international open · 2025Article
- CT-based delta-radiomics nomogram to predict pathological complete response after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma patients.Journal of translational medicine · 2024Article
- Opportunities and challenges in combining immunotherapy and radiotherapy in esophageal cancer.Journal of cancer research and clinical oncology · 2023Review
- Endoscopic Evaluation of Pathological Complete Response Using Deep Neural Network in Esophageal Cancer Patients Who Received Neoadjuvant Chemotherapy-Multicenter Retrospective Study from Four Japanese Esophageal Centers.Annals of surgical oncology · 2023Article
- A robust semi-automatic delineation workflow using denoised diffusion weighted magnetic resonance imaging for response assessment of patients with esophageal cancer treated with neoadjuvant chemoradiotherapy.Physics and imaging in radiation oncology · 2023Article
- Article
- Interim position emission tomography-computed tomography during multimodality treatment of locally advanced esophageal cancer: a scoping review.Quantitative imaging in medicine and surgery · 2023Article
- Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions.Frontiers in immunology · 2023Review
- Neoadjuvant versus definitive radiochemotherapy of locoregionally advanced oesophageal cancer-who benefits?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- Circulating Tumor DNA-Based Disease Monitoring of Patients with Locally Advanced Esophageal Cancer.Cancers · 2022Article
- FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.Journal of the National Comprehensive Cancer Network : JNCCN · 2022Article
- Review
- Review
- Diffusion-weighted MRI andRadiation oncology (London, England) · 2021Article
- Salvage Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) for T4b Esophageal Cancer After Definitive Chemoradiotherapy.Annals of surgical oncology · 2021Article
- ASO Author Reflections: Preoperative Selection of cT4b Esophageal Cancer Patients Who Benefit From a Salvage Robot-Assisted Minimally Invasive Esophagectomy (RAMIE).Annals of surgical oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundNearly one third of patients undergoing neoadjuvant chemoradiotherapy (nCRT) for locally advanced esophageal cancer have a pathologic complete response (pCR) of the primary tumor upon histopathological evaluation of the resection specimen. The primary aim of this study is to develop a model that predicts the probability of pCR to nCRT in esophageal cancer, based on diffusion-weighted magnetic resonance imaging (DW-MRI), dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and
methodsThe PRIDE study is a prospective, single arm, observational multicenter study designed to develop a multimodal prediction model for histopathological response to nCRT for esophageal cancer. A total of 200 patients with locally advanced esophageal cancer - of which at least 130 patients with adenocarcinoma and at least 61 patients with squamous cell carcinoma - scheduled to receive nCRT followed by esophagectomy will be included. The primary modalities to be incorporated in the prediction model are quantitative parameters derived from MRI and DISCUSSION: If the multimodal PRIDE concept provides high predictive performance for pCR, the results of this study will play an important role in accurate identification of esophageal cancer patients with a pCR to nCRT. These patients might benefit from a patient-tailored approach with omission of surgery in the future. Vice versa, patients with non-pCR might benefit from additional neoadjuvant treatment, or ineffective therapy could be stopped.
trial registrationThe article reports on a health care intervention on human participants and was prospectively registered on March 22, 2018 under ClinicalTrials.gov Identifier: NCT03474341 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.